Nephrology · TSC2/PKD1 Contiguous Gene Deletion Syndrome

Standard of Care and Medical Management

At a Glance

TSC2/PKD1 contiguous gene deletion syndrome requires coordinated kidney and neurologic care. Treatment includes blood pressure control, selected medicines for kidney tumors or seizures, regular brain imaging, and individualized planning for dialysis or transplant.

The medical management of TSC2/PKD1 contiguous gene deletion syndrome (CGS) requires a proactive, “dual-track” approach. Because the condition affects both the kidneys and the neurological system, care must be closely coordinated between specialists, ideally led by a team at a dedicated TSC Clinic or center of excellence ^[1]^[2].

Note: Because this syndrome is rare, many recommendations are based on expert consensus from the TSC and ADPKD guidelines rather than syndrome-specific clinical trials.

Kidney Management

The primary goal of kidney care is to preserve function and manage the complications of early-onset cysts and tumors.

Hypertension (High Blood Pressure): Controlling blood pressure is a major kidney-protective intervention within broader CKD care ^[2]. Doctors typically use ACE inhibitors (such as lisinopril) or ARBs (such as losartan) because they help protect the kidney’s delicate filtering units ^[3]^[4]. Important Safety Note: These medications require follow-up laboratory checks of creatinine and potassium. They should not be combined casually, and families must know “sick-day rules” (e.g., stopping them temporarily during severe vomiting/dehydration) to protect the kidneys from acute injury ^[4].
mTOR Inhibitors for AMLs: For growing kidney tumors called angiomyolipomas (AMLs), medications called mTOR inhibitors (specifically everolimus) may be considered ^[5]^[2]. The decision to use them depends on tumor growth, bleeding risk, kidney function, and whether kidney-sparing surgery or embolization is more appropriate. Oral mTOR inhibitors require careful monitoring for side effects, including stomatitis (mouth sores), increased infection risk, high cholesterol/lipids, impaired wound healing, and drug interactions ^[2].
The Status of Tolvaptan: Tolvaptan is an established treatment to slow cyst growth in adults with typical ADPKD. However, it is not a routine, established therapy for children with this specific deletion syndrome ^[6]^[7]. Its pediatric use is often off-label, jurisdiction-dependent, or part of a research study, and it carries substantial risks, including liver injury, excessive urination (polyuria), intense thirst, and dehydration ^[6]^[8]. It should only be considered by an experienced nephrologist with a defined monitoring plan.

Neurological and Epilepsy Management

Managing the brain-related aspects of the syndrome focuses on early detection and control of seizures, which is critical for developmental health.

Infantile Spasms: If an infant develops suspected spasms, they require urgent neurologic evaluation, not just a routine follow-up. Vigabatrin is an appropriate first-line treatment for TSC-associated infantile spasms, but alternatives or hormonal therapies may be needed depending on the specialist’s assessment ^[9]^[10].
Drug-Resistant Seizures: For seizures not well-controlled by standard antiseizure medications, everolimus is sometimes used as an “adjunctive” (add-on) therapy ^[11]^[12]. However, it is not a generic treatment for all seizures; its use depends on age, seizure type, and specialist indications, and requires significant monitoring. Epilepsy surgery may also be an option ^[13].
SEGA Monitoring: Subependymal giant cell astrocytomas (SEGA) are benign brain tumors that require regular MRI monitoring ^[2]. If a SEGA grows or blocks fluid flow, it can be treated with everolimus or surgical removal ^[14]^[15].

TSC Manifestation Management

Skin Care: Facial bumps (angiofibromas) can sometimes be treated with topical mTOR inhibitor creams (like sirolimus gel) applied directly to the skin ^[16]. While it reduces systemic side effects compared to oral medication, topical treatment is formulation-specific and can still cause local irritation or some systemic absorption.

Planning for Kidney Replacement Therapy

If the kidneys eventually reach a point where they can no longer function—known as End-Stage Kidney Disease (ESKD)—families and doctors will begin planning for dialysis or a transplant.

Nephrectomy Considerations: Because the kidneys in this syndrome can become very large and may contain bleeding-prone AMLs, surgical planning is complex ^[17]^[18]. Removing one or both native kidneys (nephrectomy) is an individualized decision made by the surgical/nephrology team, not an automatic expected step. It may be considered for severe space limitation, recurrent bleeding, infection, or chronic pain ^[19]^[20].
Transplant Realities: Kidney transplantation treats kidney failure and has been successful in patients with this syndrome ^[18]. However, transplantation does not cure the condition; it does not remove the TSC-related seizure, SEGA, skin, or developmental risks, and the patient will continue to need multidisciplinary monitoring ^[18].

Common questions in this guide

How is TSC2/PKD1 contiguous gene deletion syndrome treated?

Care uses a coordinated kidney-and-neurology approach. Treatment may include blood pressure control, monitoring or treating kidney angiomyolipomas, seizure treatment, brain MRI surveillance, and planning for dialysis or kidney transplantation when needed. A TSC clinic or center experienced with the condition can help coordinate specialists.

What blood pressure medicines are commonly used in this syndrome?

ACE inhibitors, such as lisinopril, or angiotensin receptor blockers, such as losartan, are commonly used to control blood pressure and protect kidney function. Doctors usually check blood creatinine and potassium after starting or changing these medicines. Families should ask for clear sick-day instructions during severe vomiting, dehydration, or infection and should not combine these medicines without medical guidance.

When might everolimus be recommended?

Everolimus may be considered for a growing kidney angiomyolipoma, selected drug-resistant seizures as add-on treatment, or a growing subependymal giant cell astrocytoma, also called a SEGA, that blocks fluid flow or causes concern. The choice depends on the tumor, seizure type, age, kidney function, bleeding risk, and other treatments. Monitoring is needed because everolimus can cause mouth sores, infections, high blood lipids, delayed wound healing, and drug interactions.

What should happen if an infant with this syndrome has possible spasms?

Possible infantile spasms need urgent neurologic assessment rather than waiting for a routine visit. Vigabatrin is an appropriate first-line treatment for tuberous sclerosis-associated infantile spasms, although a specialist may recommend hormonal therapy or another option depending on the evaluation. Early treatment is important because uncontrolled spasms can affect development.

Is tolvaptan routinely used for children with TSC2/PKD1 syndrome?

No. Tolvaptan is an established treatment for slowing cyst growth in some adults with typical ADPKD, but it is not a routine, established treatment for children with this deletion syndrome. If an experienced nephrologist considers it, the plan should address possible liver injury, excessive urination, intense thirst, dehydration, and close monitoring.

When might removal of a native kidney be considered?

Nephrectomy, or removal of a native kidney, is an individualized decision rather than an automatic step. The surgical and nephrology team may consider it when very large kidneys cause severe space limitations, recurrent bleeding, infection, or chronic pain. The benefits and risks should be reviewed for the specific patient, especially when dialysis or transplantation is being planned.

Does a kidney transplant cure TSC2/PKD1 syndrome?

No. A kidney transplant can treat kidney failure, but it does not remove the underlying tuberous sclerosis features or eliminate seizure, SEGA, skin, or developmental risks. Ongoing multidisciplinary monitoring is still needed after transplant.

Get notified when new evidence is published on Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Care is best coordinated through a TSC clinic with nephrology, neurology, and other specialists because the syndrome affects the kidneys and nervous system.
ACE inhibitors or ARBs can help control blood pressure and protect kidney function, but kidney blood tests and sick-day instructions are important.
Everolimus may be used selectively for growing kidney angiomyolipomas, certain drug-resistant seizures, or problematic SEGAs, with monitoring for side effects.
Suspected infantile spasms require urgent neurologic evaluation, and vigabatrin is an appropriate first-line treatment for tuberous sclerosis-associated spasms.
Nephrectomy is considered for selected kidney complications, while dialysis and transplantation are planned for kidney failure; transplantation does not eliminate tuberous sclerosis-related risks.

References (20)

1
A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report.
Auvin S, Bissler JJ, Cottin V, et al.
Orphanet journal of rare diseases 2019; (14(1)):91 doi:10.1186/s13023-019-1072-y.
PMID: 31039793
2
Tuberous sclerosis complex-associated kidney disease in children.
Marlais M, Mekahli D
Pediatric nephrology (Berlin, Germany) 2025; (40(6)):1871-1877 doi:10.1007/s00467-024-06642-9.
PMID: 39814976
3
Progressive Polycystic Kidney Disease in an Infant Girl With TSC2/PKD1 Contiguous Gene Syndrome.
Hashimoto K, Hayashida T, Otsubo Y, et al.
Cureus 2024; (16(8)):e67800 doi:10.7759/cureus.67800.
PMID: 39323690
4
Blood pressure and glomerular filtration rate in youth with tuberous sclerosis complex.
Vargiami E, Stabouli S, Sidira C, et al.
European journal of pediatrics 2022; (181(4)):1465-1472 doi:10.1007/s00431-021-04333-3.
PMID: 34988664
5
Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clinical journal of the American Society of Nephrology : CJASN 2017; (12(7)):1196-1202 doi:10.2215/CJN.08150816.
PMID: 28302901
6
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, et al.
Clinical journal of the American Society of Nephrology : CJASN 2023; (18(1)):36-46 doi:10.2215/CJN.0000000000000022.
PMID: 36719158
7
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Torres VE, Higashihara E, Devuyst O, et al.
Clinical journal of the American Society of Nephrology : CJASN 2016; (11(5)):803-811 doi:10.2215/CJN.06300615.
PMID: 26912543
8
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Watkins PB, Lewis JH, Kaplowitz N, et al.
Drug safety 2015; (38(11)):1103-13 doi:10.1007/s40264-015-0327-3.
PMID: 26188764
9
Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.
van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM
Paediatric drugs 2020; (22(1)):73-84 doi:10.1007/s40272-019-00376-0.
PMID: 31912454
10
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.
Curatolo P, Nabbout R, Lagae L, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(5)):738-748 doi:10.1016/j.ejpn.2018.05.006.
PMID: 29880258
11
Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
Lechuga L, Franz DN
Expert review of neurotherapeutics 2019; (19(10)):913-925 doi:10.1080/14737175.2019.1635457.
PMID: 31335226
12
Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine.
Schubert-Bast S, Strzelczyk A
Therapeutic advances in neurological disorders 2021; (14()):17562864211031100 doi:10.1177/17562864211031100.
PMID: 34349839
13
Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy.
Specchio N, Nabbout R, Aronica E, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2023; (47()):25-34 doi:10.1016/j.ejpn.2023.08.005.
PMID: 37669572
14
Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.
Arroyo MS, Krueger DA, Broomall E, et al.
Pediatric neurology 2017; (72()):81-85 doi:10.1016/j.pediatrneurol.2017.04.008.
PMID: 28511812
15
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.
Jóźwiak S, Mandera M, Młynarski W
Seminars in pediatric neurology 2015; (22(4)):274-81.
PMID: 26706014
16
TSC2/PKD1 contiguous deletion syndrome in a pregnant woman: A case report.
Huang S, Xu K, Xu Y, et al.
Frontiers in medicine 2023; (10()):1101079 doi:10.3389/fmed.2023.1101079.
PMID: 36895714
17
Imaging features of TSC2/PKD1 contiguous gene deletion syndrome in adults.
Bitton J, Boudhabhay I, Dariane C, et al.
Abdominal radiology (New York) 2026; doi:10.1007/s00261-026-05768-8.
PMID: 42696112
18
Renal angiomyolipoma bleeding in a patient with TSC2/PKD1 contiguous gene syndrome after 17 years of renal replacement therapy.
Furlano M, Barreiro Y, Martí T, et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2017; (37(1)):87-92 doi:10.1016/j.nefro.2016.04.007.
PMID: 27595512
19
The Need for Routine Native Nephrectomy in the Workup for Kidney Transplantation in Autosomal Dominant Polycystic Kidney Disease Patients.
Casteleijn NF, Geertsema P, Koorevaar IW, et al.
Urologia internationalis 2023; (107(2)):148-156 doi:10.1159/000525575.
PMID: 35810740
20
Simultaneous nephrectomy during kidney transplantation for polycystic kidney disease does not detrimentally impact comorbidity and graft survival.
Darius T, Bertoni S, De Meyer M, et al.
World journal of transplantation 2022; (12(5)):100-111 doi:10.5500/wjt.v12.i5.100.
PMID: 35663541

This page is for informational purposes only and does not constitute medical advice. Management of TSC2/PKD1 contiguous gene deletion syndrome should be individualized with the patient's TSC, nephrology, neurology, and transplant teams.